Nephros, Inc.
380 Lackawanna Place
South Orange, New Jersey 07079
(201) 343-5202
May 16, 2019
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Timothy Buchmiller
Re: | Nephros, Inc. (the “Company”) | |
Post-Effective Amendment to Registration Statement on Form S-1 | ||
File No. 333-205169 |
Dear Mr. Buchmiller:
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Nephros, Inc. (the “Registrant”), hereby requests withdrawal, effective immediately, of the Post-Effective Amendment (the “Amendment”) to its Registration Statement on Form S-1 (File No. 333-205169) (the “Registration Statement”), together with all exhibits thereto.
The Registrant separately filed a Post-Effective Amendment to Registration Statement on Form S-1 (File No. 333-225109) that, pursuant to Rule 429 under the Securities Act, also constituted a post-effective amendment to the Registration Statement. Accordingly, the Amendment has been superseded.
The Amendment was initially filed with the Securities and Exchange Commission on May 9, 2019. No securities were sold pursuant to the Amendment, and the Amendment was never declared effective.
Please contact Amanda Lorentz of Fredrikson & Byron, P.A. at (612) 492-7403 if you have any questions.
Sincerely, | ||
Nephros, Inc. | ||
By: | /s/ Daron Evans | |
Daron Evans | ||
Chief Executive Officer |